Compare BQ & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BQ | LEXX |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.7M |
| IPO Year | 2020 | 2011 |
| Metric | BQ | LEXX |
|---|---|---|
| Price | $0.97 | $11.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 4.5M | 94.1K |
| Earning Date | 01-05-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.65 | $0.35 |
| 52 Week High | $72.74 | $12.89 |
| Indicator | BQ | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 90.20 |
| Support Level | $0.70 | $0.65 |
| Resistance Level | $1.41 | N/A |
| Average True Range (ATR) | 0.18 | 1.04 |
| MACD | 0.01 | 0.56 |
| Stochastic Oscillator | 16.63 | 78.41 |
Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.